RU58841 lacks FDA approval due to financial and safety concerns, including potential cardiological side effects. The company abandoned further research, and users report adverse effects like heart palpitations and gynecomastia.
Microneedle pens for hair loss are harder to find on Amazon due to FDA regulations on needle length. Users suggest buying from AliExpress or Temu instead.
A user questions the authenticity of a cheap minoxidil product due to packaging errors and unusual smell, considering returning it. They also reference an FDA report for further information.
Hair loss treatments discussed include Minoxidil, finasteride, and RU58841. There is skepticism about claims of a breakthrough, despite FDA approval for human trials.
Cosmo Pharma plans to release Breezula, a hair loss treatment, with expected FDA approval in 2027, but concerns arise over its high potential cost of $225/month. Users express skepticism about its effectiveness compared to cheaper alternatives like finasteride and minoxidil.
The conversation is about starting microneedling for hair growth, with questions on needle sizes, session frequency, and reliable purchasing options. The user seeks clarity on FDA regulations and prefers to avoid certain online retailers.
The conversation is about the effectiveness and safety of a hair loss treatment called Pyri, with users discussing its availability and comparing it to other treatments like RU58841, fluridil, and alfatradiol. Some users are waiting for FDA approval before using Pyri, while others share their positive experiences with RU58841 and suggest additional treatments with minimal side effects.
Hair loss discussion includes treatments like Minoxidil, Finasteride, and RU58841. Eucapil's effectiveness is questioned due to unconvincing clinical trial and lack of FDA approval.
The conversation is about the availability of hair loss treatments Breezula, SM04554, Follica FOL-004, and Follicum FOL-005 in Canada after FDA approval, including potential delays, loopholes for obtaining them, and insurance coverage.
Setipiprant and bimatoprost are being discussed as potential future treatments for hair loss. Some individuals have started testing setipiprant before FDA approval, but no progress updates are available yet.
A user is considering exosome therapy from Springs Rejuvenation for hair loss after unsuccessful attempts with PRP, adipose injections, and a laser cap. They are intrigued by the therapy's potential and the clinic's guarantee of 30% improved coverage, despite concerns about FDA approval and high-pressure sales tactics.
The user experienced a slight decrease in hair shedding and scalp itch, and reduced sebum production using Pyrilutamide, but stopped due to chest pain, breathing difficulties, and heart issues. They felt normal a week after discontinuing and doubted FDA approval for the drug.
France is considering reviewing finasteride and dutasteride due to concerns about their safety, but a ban in the EU is unlikely due to regulatory hurdles. Many users express frustration over the potential ban, emphasizing the effectiveness of finasteride for hair loss and criticizing the influence of anecdotal evidence on public health policy.
The conversation discusses the effectiveness of Exosomes as a hair loss treatment. A user recalls a doctor on Youtube showcasing successful results from using Exosomes.
People are using lower doses of finasteride than the recommended 1mg daily due to concerns about side effects, cost, and new data suggesting lower doses can be nearly as effective. Some users report stability or slight improvements with lower doses, but the effectiveness compared to 1mg daily is debated.
A pharmacy error resulted in a finasteride solution being 100 times stronger than prescribed, not 10,000 times as initially feared. OP is advised to contact the pharmacy to clarify the preparation before traveling.
The user is considering reducing RU58841 dosage from 100mg to 17.5mg for long-term safety due to brain fog issues from finasteride. They apply RU58841 only to the front of the scalp where thinning occurs.
A 21-year-old with diffuse thinning hair is considering RU58841 due to side effects from topical finasteride and is asking for the lowest effective dose and time to see results from RU58841 users.
The user is considering reducing their finasteride dose from 2.5mg to 1.25mg to make the supply last longer and is concerned about potential changes in results. They have been using the 2.5mg dose for four months.
The user is experiencing a lack of morning erections after using 0.5mg of finasteride every other day for two weeks and is considering whether to reduce the dose, continue, or stop. The discussion focuses on adjusting finasteride dosage due to side effects.
The user experienced side effects with 1mg finasteride and is considering using a 0.5mg dose to prevent them. Another user suggested splitting the pills to achieve the lower dose.
A user was prescribed 5mg of Finasteride daily for hair loss, which is a higher dose typically used for prostate issues. Many suggest using a pill cutter to reduce the dose to 1mg or less per day, as it is more cost-effective and equally effective for hair loss.
Oral minoxidil dosing should be based on body weight to minimize side effects, with higher doses increasing risks like pericardial effusion. Combining oral minoxidil with topical treatments and finasteride can improve hair growth, but regular heart health monitoring is essential.
Low-dose dutasteride (0.1 mg) is effective for hair growth, potentially more so than finasteride, with fewer side effects. East Asians may respond well to these treatments due to hair characteristics.